Smith & Nephew (LON:SN) Earns Outperform Rating from Royal Bank of Canada

Smith & Nephew (LON:SN)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank of Canada in a research report issued on Friday, Marketbeat Ratings reports. They presently have a GBX 1,500 ($18.83) price target on the stock. Royal Bank of Canada’s price target would indicate a potential upside of 53.88% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 1,300 ($16.32) price target on shares of Smith & Nephew in a research report on Wednesday. Barclays reissued an “equal weight” rating and issued a GBX 1,150 ($14.44) price target on shares of Smith & Nephew in a research report on Friday, February 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,362.50 ($17.10).

Smith & Nephew Price Performance

Smith & Nephew stock opened at GBX 974.80 ($12.24) on Friday. The stock has a market cap of £8.52 billion, a P/E ratio of 4,061.67, a price-to-earnings-growth ratio of 0.52 and a beta of 0.51. The company has a fifty day simple moving average of GBX 1,073.14 and a 200-day simple moving average of GBX 1,038.29. Smith & Nephew has a 12-month low of GBX 887 ($11.13) and a 12-month high of GBX 1,316.75 ($16.53). The company has a current ratio of 1.77, a quick ratio of 0.84 and a debt-to-equity ratio of 59.11.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.